{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:32:48Z","timestamp":1790742768291,"version":"4.1.0"},"reference-count":105,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is\u00a0diminished in hematopoietic stem cell transplant (HSCT) recipients. To summarize current evidence and identify risk factors for attenuated responses, 5 electronic databases were searched\u00a0since database inceptions through 12 January 2023 for studies reporting humoral and\/or cellular immunogenicity of SARS-CoV-2 vaccination in the HSCT population. Using descriptive statistics and random-effects models, extracted numbers of responders and pooled odds ratios (pORs) with 95% confidence intervals (CIs) for risk factors of negative immune responses were analyzed (PROSPERO: CRD42021277109). From 61 studies with 5906 HSCT recipients, after 1, 2, and 3 doses of messenger RNA (mRNA) SARS-CoV-2 vaccines, the mean antispike antibody seropositivity rates (95% CI) were 38% (19-62), 81% (77-84), and 80% (75-84); neutralizing antibody seropositivity rates were 52% (40-64), 71% (54-83), and 78% (61-89); and cellular immune response rates were 52% (39-64), 66% (51-79), and 72% (52-86). After 2 vaccine doses, risk factors (pOR; 95%\u00a0CI) associated with antispike seronegativity were male recipients (0.63; 0.49-0.83), recent rituximab exposure (0.09; 0.03-0.21), haploidentical allografts (0.46; 0.22-0.95), &amp;lt;24\u00a0months from HSCT (0.25; 0.07-0.89), lymphopenia (0.18; 0.13-0.24), hypogammaglobulinemia (0.23; 0.10-0.55), concomitant chemotherapy (0.48; 0.29-0.78) and immunosuppression (0.18; 0.13-0.25). Complete remission of underlying hematologic malignancy (2.55; 1.05-6.17) and myeloablative conditioning (1.72; 1.30-2.28) compared with reduced-intensity conditioning were associated with antispike seropositivity. Ongoing immunosuppression (0.31; 0.10-0.99) was associated with poor cellular immunogenicity. In conclusion, attenuated humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination are associated with several risk factors among HSCT recipients. Optimizing individualized vaccination and developing alternative COVID-19 prevention strategies are warranted.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010349","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:14:20Z","timestamp":1688138060000},"page":"5624-5636","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-7096","authenticated-orcid":false,"given":"Tanaporn","family":"Meejun","sequence":"first","affiliation":[{"name":"1Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-6344","authenticated-orcid":false,"given":"Karan","family":"Srisurapanont","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-143X","authenticated-orcid":false,"given":"Kasama","family":"Manothummetha","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-1062","authenticated-orcid":false,"given":"Achitpol","family":"Thongkam","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-3578","authenticated-orcid":false,"given":"Nuthchaya","family":"Mejun","sequence":"additional","affiliation":[{"name":"4Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-637X","authenticated-orcid":false,"given":"Nipat","family":"Chuleerarux","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Miami\/Jackson Memorial Hospital, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-4136","authenticated-orcid":false,"given":"Anawin","family":"Sanguankeo","sequence":"additional","affiliation":[{"name":"6Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0656-5120","authenticated-orcid":false,"given":"Kasidis","family":"Phongkhun","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-3056","authenticated-orcid":false,"given":"Surachai","family":"Leksuwankun","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-5387","authenticated-orcid":false,"given":"Jaedvara","family":"Thanakitcharu","sequence":"additional","affiliation":[{"name":"8Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-6407","authenticated-orcid":false,"given":"Bhoowit","family":"Lerttiendamrong","sequence":"additional","affiliation":[{"name":"4Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-7122","authenticated-orcid":false,"given":"Nattapong","family":"Langsiri","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6339","authenticated-orcid":false,"given":"Pattama","family":"Torvorapanit","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"},{"name":"9Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-6830","authenticated-orcid":false,"given":"Navaporn","family":"Worasilchai","sequence":"additional","affiliation":[{"name":"10Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-1209","authenticated-orcid":false,"given":"Rongpong","family":"Plongla","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-6856","authenticated-orcid":false,"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1120","authenticated-orcid":false,"given":"Saman","family":"Nematollahi","sequence":"additional","affiliation":[{"name":"11Department of Medicine, University of Arizona College of Medicine, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-7342","authenticated-orcid":false,"given":"Nitipong","family":"Permpalung","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"3Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-0867","authenticated-orcid":false,"given":"Chatphatai","family":"Moonla","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"},{"name":"12Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-0049","authenticated-orcid":false,"given":"Olivia S.","family":"Kates","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"2","key":"2023092214245978700_bib1","doi-asserted-by":"crossref","first-page":"e13792","DOI":"10.1111\/tid.13792","article-title":"Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"24","author":"Shahzad","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"20","key":"2023092214245978700_bib2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023092214245978700_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2023092214245978700_bib4","doi-asserted-by":"crossref","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"24","key":"2023092214245978700_bib5","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/bloodadvances.2022008530","article-title":"Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis","volume":"6","author":"Chuleerarux","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023092214245978700_bib6","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1038\/s41467-022-33864-y","article-title":"Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"Nat Commun"},{"key":"2023092214245978700_bib7","unstructured":"US Food and Drug Administration\n          . FDA announces Evusheld is not currently authorized for emergency use in the U.S. Accessed 5 March 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us."},{"issue":"23","key":"2023092214245978700_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6\u00a0months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2023092214245978700_bib9","unstructured":"Centers for Disease Control and Prevention\n          . Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Accessed 29 January 2023. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html."},{"issue":"12","key":"2023092214245978700_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-022-00776-5","article-title":"Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis","volume":"12","author":"Uaprasert","year":"2022","journal-title":"Blood Cancer J"},{"key":"2023092214245978700_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023092214245978700_bib12","unstructured":"Wells\n              G\n            , SheaB, O\u2019ConnellD, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 29 January 2023. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"29","key":"2023092214245978700_bib13","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"2023092214245978700_bib14","author":"Higgins","year":"2019","edition":"2nd ed"},{"issue":"7109","key":"2023092214245978700_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"2023092214245978700_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"4","key":"2023092214245978700_bib17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"4","key":"2023092214245978700_bib18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2022.02.010","article-title":"Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients","volume":"40","author":"Abid","year":"2022","journal-title":"Cancer Cell"},{"issue":"9","key":"2023092214245978700_bib19","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/v14091928","article-title":"Third early \u201cbooster\u201d dose strategy in France of BNT162b2 SARS-CoV-2 vaccine in allogeneic hematopoietic stem cell transplant recipients enhances neutralizing antibody responses","volume":"14","author":"Ahmed-Belkacem","year":"2022","journal-title":"Viruses"},{"issue":"4","key":"2023092214245978700_bib20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjh.17873","article-title":"Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients","volume":"196","author":"Attolico","year":"2022","journal-title":"Br J Haematol"},{"key":"2023092214245978700_bib21","doi-asserted-by":"crossref","first-page":"897937","DOI":"10.3389\/fonc.2022.897937","article-title":"Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience","volume":"12","author":"Autore","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"2023092214245978700_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2023092214245978700_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/bjh.18562","article-title":"Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation","volume":"201","author":"Bankova","year":"2023","journal-title":"Br J Haematol"},{"issue":"23","key":"2023092214245978700_bib24","first-page":"8984","article-title":"Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the\u00a0BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Barabino","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"2023092214245978700_bib25","doi-asserted-by":"crossref","first-page":"e13828","DOI":"10.1111\/tid.13828","article-title":"Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation","volume":"24","author":"Beerlage","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2023092214245978700_bib26","doi-asserted-by":"crossref","first-page":"899972","DOI":"10.3389\/fimmu.2022.899972","article-title":"Reduced antibodies and innate cytokine changes in SARS-CoV-2 BNT162b2 mRNA vaccinated transplant patients with hematological malignancies","volume":"13","author":"Bergamaschi","year":"2022","journal-title":"Front Immunol"},{"key":"2023092214245978700_bib27","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"2023092214245978700_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"2023092214245978700_bib29","doi-asserted-by":"crossref","first-page":"737300","DOI":"10.3389\/fonc.2021.737300","article-title":"Immunological response against SARS-CoV-2 after BNT162b2 vaccine administration is impaired in allogeneic but not in autologous stem cell transplant recipients","volume":"11","author":"Chiarucci","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2023092214245978700_bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/vaccines10030448","article-title":"SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine","volume":"10","author":"Cl\u00e9menceau","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"19","key":"2023092214245978700_bib31","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3390\/cells11193010","article-title":"Strong SARS-CoV-2 T-cell responses after one or two COVID-19 vaccine boosters in allogeneic hematopoietic stem cell recipients","volume":"11","author":"Cl\u00e9menceau","year":"2022","journal-title":"Cells"},{"issue":"33","key":"2023092214245978700_bib32","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1016\/j.vaccine.2022.07.006","article-title":"Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients","volume":"40","author":"Cuffel","year":"2022","journal-title":"Vaccine"},{"issue":"14","key":"2023092214245978700_bib33","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2023092214245978700_bib34","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.jtct.2021.07.011","article-title":"Serologic responses following a single dose of SARS-CoV-2 vaccination in allogeneic stem cell transplantation recipients","volume":"27","author":"Easdale","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023092214245978700_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2022.02.011","article-title":"Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"2023092214245978700_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2021.280494","article-title":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation","volume":"107","author":"Einarsdottir","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"2023092214245978700_bib37","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2021006937","article-title":"Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity","volume":"6","author":"Einarsdottir","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2023092214245978700_bib38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41409-022-01675-w","article-title":"Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients","volume":"57","author":"Gavriilaki","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023092214245978700_bib39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"2023092214245978700_bib40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","article-title":"Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients","volume":"6","author":"Haggenburg","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2023092214245978700_bib41","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023092214245978700_bib42","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ccell.2021.10.002","article-title":"Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients","volume":"39","author":"Harrington","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"2023092214245978700_bib43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2023092214245978700_bib44","doi-asserted-by":"crossref","first-page":"214.e1","DOI":"10.1016\/j.jtct.2022.01.019","article-title":"Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation","volume":"28","author":"Huang","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2023092214245978700_bib45","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/eji.202149771","article-title":"SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination","volume":"52","author":"Jarisch","year":"2022","journal-title":"Eur J Immunol"},{"issue":"3","key":"2023092214245978700_bib46","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2023092214245978700_bib47","doi-asserted-by":"crossref","first-page":"706.e1","DOI":"10.1016\/j.jtct.2022.07.024","article-title":"Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients","volume":"28","author":"Kimura","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2023092214245978700_bib48","doi-asserted-by":"crossref","first-page":"e2126344","DOI":"10.1001\/jamanetworkopen.2021.26344","article-title":"Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant","volume":"4","author":"Le Bourgeois","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2023092214245978700_bib49","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17911","article-title":"Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant","volume":"196","author":"Le Bourgeois","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"2023092214245978700_bib50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/vaccines9101075","article-title":"Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients","volume":"9","author":"Lindemann","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"2023092214245978700_bib51","doi-asserted-by":"crossref","first-page":"388.e1","DOI":"10.1016\/j.cmi.2022.10.009","article-title":"One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort","volume":"29","author":"Loubet","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2023092214245978700_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood.2021014232","article-title":"Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients","volume":"139","author":"Maillard","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023092214245978700_bib53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/cancers14020325","article-title":"Two doses of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral response and serological conversion predictors","volume":"14","author":"Majcherek","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2023092214245978700_bib54","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1038\/s41409-021-01466-9","article-title":"Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"56","author":"Mamez","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023092214245978700_bib55","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"2023092214245978700_bib56","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/vaccines9101209","article-title":"The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation","volume":"9","author":"Matkowska-Kocjan","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"2023092214245978700_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.26769","article-title":"Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: a Japanese multicenter observational study","volume":"98","author":"Mori","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2023092214245978700_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.18312","article-title":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant","volume":"198","author":"Murray","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"2023092214245978700_bib59","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","article-title":"Antibody response to COVID-19 vaccination in patients with lymphoma","volume":"115","author":"Narita","year":"2022","journal-title":"Int J Hematol"},{"issue":"3","key":"2023092214245978700_bib60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jiac.2022.11.010","article-title":"Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: an observational study","volume":"29","author":"Nishikubo","year":"2023","journal-title":"J\u00a0Infect Chemother"},{"issue":"2","key":"2023092214245978700_bib61","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/vaccines10020330","article-title":"Humoral responses and chronic GVHD exacerbation after COVID-19 vaccination post allogeneic stem cell transplantation","volume":"10","author":"Pabst","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2023092214245978700_bib62","doi-asserted-by":"crossref","first-page":"892331","DOI":"10.3389\/fimmu.2022.892331","article-title":"Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients","volume":"13","author":"Pascale","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"2023092214245978700_bib63","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"2023092214245978700_bib64","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1097\/HS9.0000000000000686","article-title":"Serologic responses to COVID-19 vaccines in hematological patients are predominantly impaired in lymphoid but not in myeloid malignancies","volume":"6","author":"Petzer","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2023092214245978700_bib65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.26385","article-title":"SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group","volume":"97","author":"Pi\u00f1ana","year":"2022","journal-title":"Am J Hematol"},{"key":"2023092214245978700_bib66","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9","key":"2023092214245978700_bib67","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2023092214245978700_bib68","first-page":"2803","article-title":"Early cellular and humoral responses developed in oncohematological patients after vaccination with one dose against COVID-19","volume":"11","author":"Rodr\u00edguez-Mora","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"12","key":"2023092214245978700_bib69","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1002\/ajh.26373","article-title":"Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis","volume":"96","author":"Schiller Salton","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2023092214245978700_bib70","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/j.clml.2021.11.001","article-title":"COVID-19 vaccine responses in patients with plasma cell dyscrasias after complete vaccination","volume":"22","author":"Shah","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2023092214245978700_bib71","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023092214245978700_bib72","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1093\/cid\/ciab930","article-title":"SARS-CoV-2 mRNA vaccines in allogeneic hematopoietic stem cell transplant recipients: immunogenicity and reactogenicity","volume":"75","author":"Sherman","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2023092214245978700_bib73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-021-00594-1","article-title":"Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies","volume":"11","author":"Tamariz-Amador","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023092214245978700_bib74","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cas.15603","article-title":"Attenuated humoral response against SARS-CoV-2 mRNA vaccination in allogeneic stem cell transplantation recipients","volume":"114","author":"Toya","year":"2023","journal-title":"Cancer Sci"},{"issue":"5","key":"2023092214245978700_bib75","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12185-022-03325-9","article-title":"Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation","volume":"115","author":"Tsushima","year":"2022","journal-title":"Int J Hematol"},{"issue":"2","key":"2023092214245978700_bib76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/vaccines10020158","article-title":"The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation","volume":"10","author":"Watanabe","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"2023092214245978700_bib77","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/vaccines10111830","article-title":"A third dose COVID-19 vaccination in allogeneic hematopoietic stem cell transplantation patients","volume":"10","author":"Watanabe","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"2023092214245978700_bib78","doi-asserted-by":"crossref","first-page":"303.e1","DOI":"10.1016\/j.cmi.2021.10.007","article-title":"Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation","volume":"28","author":"Yeshurun","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"2023092214245978700_bib79","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/infdis\/jiac188","article-title":"Humoral immunogenicity of the mRNA-1273 vaccine in the phase 3 Coronavirus Efficacy (COVE) trial","volume":"226","author":"El Sahly","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"2023092214245978700_bib80","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023092214245978700_bib81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-022-01250-2","article-title":"Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Leclerc","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"2023092214245978700_bib82","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/bmt.2009.255","article-title":"Background to hematopoietic cell transplantation, including post transplant immune recovery","volume":"44","author":"Mackall","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2023092214245978700_bib83","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"23","key":"2023092214245978700_bib84","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.3390\/cancers13236140","article-title":"Vaccine responses in adult hematopoietic stem cell transplant recipients: a comprehensive review","volume":"13","author":"Janssen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023092214245978700_bib85","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2023092214245978700_bib86","first-page":"961","article-title":"A\u00a0comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT","volume":"18","author":"Parkkali","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023092214245978700_bib87","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bmt.1703239","article-title":"Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients","volume":"28","author":"Gandhi","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2023092214245978700_bib88","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.vaccine.2010.01.025","article-title":"Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial","volume":"28","author":"Cordonnier","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"2023092214245978700_bib89","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2018.11.053","article-title":"Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Langedijk","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"2023092214245978700_bib90","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/s41409-021-01437-0","article-title":"Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"56","author":"Janssen","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023092214245978700_bib91","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2008.229","article-title":"Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?","volume":"42","author":"Buser","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023092214245978700_bib92","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbmt.2013.11.028","article-title":"Immune reconstitution after haploidentical hematopoietic stem cell transplantation","volume":"20","author":"Chang","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023092214245978700_bib93","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023092214245978700_bib94","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/sj.leu.2404681","article-title":"Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens","volume":"21","author":"Jim\u00e9nez","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"2023092214245978700_bib95","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14760584.2015.966694","article-title":"Sexual dimorphism in immunity: improving our understanding of vaccine immune responses in men","volume":"14","author":"Furman","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"2023092214245978700_bib96","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","article-title":"Donor and recipient sex in allogeneic stem cell transplantation: what really matters","volume":"101","author":"Kim","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2023092214245978700_bib97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(21)00346-6","article-title":"Sexual dimorphism in COVID-19: potential clinical and public health implications","volume":"10","author":"Bechmann","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2023092214245978700_bib98","doi-asserted-by":"crossref","first-page":"e2247534","DOI":"10.1001\/jamanetworkopen.2022.47534","article-title":"Assessment of COVID-19 incidence and severity among recipients of allogeneic stem cell transplant after 1 or 2 mRNA booster doses during the Omicron wave in France","volume":"5","author":"Letailleur","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023092214245978700_bib99","doi-asserted-by":"crossref","first-page":"e1003917","DOI":"10.1371\/journal.pmed.1003917","article-title":"COVID-19 prophylaxis in immunosuppressed patients: beyond vaccination","volume":"19","author":"Gentile","year":"2022","journal-title":"PLoS Med"},{"issue":"23","key":"2023092214245978700_bib100","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023092214245978700_bib101","doi-asserted-by":"crossref","first-page":"e0077522","DOI":"10.1128\/jvi.00775-22","article-title":"A\u00a0bispecific antibody targeting RBD and S2 potently neutralizes SARS-CoV-2 Omicron and other variants of concern","volume":"96","author":"Yuan","year":"2022","journal-title":"J\u00a0Virol"},{"issue":"1","key":"2023092214245978700_bib102","doi-asserted-by":"crossref","first-page":"112014","DOI":"10.1016\/j.celrep.2023.112014","article-title":"Bivalent intra-spike binding provides durability against emergent Omicron lineages: results from a global consortium","volume":"42","author":"Callaway","year":"2023","journal-title":"Cell Rep"},{"issue":"1","key":"2023092214245978700_bib103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-022-01300-9","article-title":"Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR\u00a0T-cell therapy recipients","volume":"15","author":"Wu","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"53","key":"2023092214245978700_bib104","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.15585\/mmwr.mm7153a1","article-title":"Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, Nine States, September-November 2022","volume":"71","author":"Tenforde","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2023092214245978700_bib105","doi-asserted-by":"crossref","first-page":"337.e1","DOI":"10.1016\/j.jtct.2023.01.025","article-title":"Impact of donor and recipient SARS-CoV-2 vaccination or infection on immunity after hematopoietic cell transplantation","volume":"29","author":"Sherman","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5624\/2079873\/blooda_adv-2023-010349-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5624\/2079873\/blooda_adv-2023-010349-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:26:09Z","timestamp":1695392769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5624\/496657\/Attenuated-immunogenicity-of-SARS-CoV-2-vaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":105,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010349","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}